A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial

Trial Profile

A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Ingenol mebutate (Primary) ; Imiquimod
  • Indications Actinic keratosis; Skin cancer
  • Focus Therapeutic Use
  • Sponsors LEO Pharma
  • Most Recent Events

    • 22 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Oct 2019.
    • 22 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2019.
    • 16 Sep 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top